TrialHuman vaccines & immunotherapeutics2024

Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults.

Prasad S Kulkarni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.